AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03184038 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT03184038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01865175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ionic iron
Description: Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine followed by 7 days of heme iron.
Study NCT01865175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ionic iron
Description: Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine followed by 7 days of heme iron.
Study NCT02908139 — intervention group
Intervention type: DEVICE
Intervention: BR-102 plus PWA
Description: Monitoring of Arterial Stiffness and Central Aortic Pressure
Study NCT02908139 — intervention group
Intervention type: DEVICE
Intervention: Tanita MC780 MA S
Description: The device measured the size of total body water (TBW), Extra Cellular Water (ECW), Intra Cellular Water (ICW), fat mass (FM%), visceral fat%, fat free mass (FFM) and basal metabolic rate, (BMR) (kcal).
Study NCT01865175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heme iron polypeptide
Description: Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
Study NCT01865175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heme iron polypeptide
Description: Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
Study NCT04136743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipogems
Description: The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the tendon lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.
Study NCT04136743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Triamcinolone Acetonide is a corticosteroid, which is a class of drugs that are commonly prescribed for shoulder pain. They work to reduce pain by limiting inflammation. They are typically injected into the subacromial space with or without ultrasound guidance.
Study NCT04461444 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Skin biopsy
Description: COBBALT is considered as an interventional with minor associated risks and constrains study due to the presence of skin biopsies that may not all be part of the usual medical practice. Risks are those linked to the biopsy procedure:~* risk of pain due to the procedure performed under local anaesthesia~* can leave a visible scar (about 2 x 1 cm)
Study NCT01636323 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Subjects will be given two doses of nicotine: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). According to the Massachusetts Department of Public Health classification, cigarettes with a nicotine yield of 1.2 mg or higher are high nicotine cigarettes. The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
Study NCT03664362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The BSHAPE Intervention
Description: The BSHAPE intervention program key elements include strengths based assessments, individualized plans and support based on priorities and needs, motivational interviewing strategies, psychoeducation (education with skill building exercises), mindfulness activities, danger assessment, safety planning, behavioral activation and linkage to community resources
Study NCT03892252 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04744493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExaBlate 4000
Description: The Exablate 4000, an advanced, non-invasive technique for performing ablation of the Thalamus for treating Essential Tremor, received FDA PMA (P150038) approval for unilateral treatment of Essential Tremor in 2016.
Study NCT02158988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC:~Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied.
Study NCT02209870 — intervention group
Intervention type: BEHAVIORAL
Intervention: E-checklist Group
Description: The patient group after E-checklist system deployed
Study NCT01511094 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goniocurettage
Description: Ab interno surgery consisting on scraped away the trabecular tissue from the angle (goniocurettage) removing segments of pathologically altered trabecular meshwork from the scleral sulcus
Study NCT03109483 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Geriatric Activation Program Pellenberg
Description: intensive multicomponent physical therapy week program
Study NCT00809796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentamidine
Description: one dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.
Study NCT01968421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OM-85 BV
Description: two courses of 7mg of OM-85 or matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
Study NCT01968421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OM-85 BV
Description: two courses of 7mg of OM-85 or matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
Study NCT02959801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous mechanical thrombectomy
Description: Aspirex catheters(Straub Medical AG, Wangs, Switzerland)
Study NCT00624091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac surgery
Description: Cardiac surgery within 48 hours of randomization
Study NCT00624091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: State-to-the-art treatment
Description: Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
Study NCT03052894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydraulic Monitoring Device
Description: The hydraulic monitoring device externally measures the pressure associated with thumb strength applied to the device to determine the depth of neuromuscular blockade during general anesthesia.~This will be compared to measurements using a current monitoring device in the same patient.
Study NCT03052894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard EMG Monitoring Device
Description: Standard and in current usage, the electromyographic monitoring (EMG) device externally measures the action potential of the muscles of the thumb to determine the depth of neuromuscular blockade during general anesthesia.~This will be used as the clinical monitoring device and as a comparator.
Study NCT02292576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa Pure
Description: Cocoa Pure.
Study NCT02292576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo.
Study NCT03012269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training
Study NCT02901223 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard quadrantectomy
Description: standard conservative surgery with no use of any plastic techniques
Study NCT02901223 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oncoplastic breast surgery
Description: Integration of plastic techniques with oncological procedures
Study NCT00515853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Biofeedback sessions or biofeedback exercises
Study NCT03103490 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 18F-FSPG
Description: Patients receive 8mCi of 18F-FSPG and undergo PET/MRI imaging (or PET/CT for patients with metal implants) to determine the ability of 18F-FSPG to localize to cardiac sarcoidosis or myocardial inflammation.
Study NCT03856385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Walking
Description: Weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
Study NCT04870229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carnosine
Study NCT04870229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02813876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced recovery protocol
Study NCT04554017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education/Training
Description: It consisted of a brief overview of hypertension, risk factors, complications and much emphasis placed on the preventive measures (what they include and why it is necessary to practice them).
Study NCT02919930 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Switch from oronasal to nasal mask during ASV treatment
Description: One night of ASV treatment with oronasal mask followed by one night of ASV treatment with nasal mask.
Study NCT02919930 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Switch from nasal to oronasal mask during ASV treatment
Description: One night of ASV treatment with nasal mask followed by one night of ASV treatment with oronasal mask.
Study NCT01395888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI)
Description: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI)
Study NCT01395888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: • Tiotropium (18 mcg) administered QD via a HandiHaler
Study NCT03278860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin
Description: 24 IU of oxytocin nasal spray will be applied to each subject.
Study NCT03278860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal placebo
Description: an identical amount of placebo nasal spray will be applied to each subject.
Study NCT02136082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asha Support + Training
Study NCT02136082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asha Support + Food
Study NCT02136082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asha Support + Training + Food
Study NCT02136082 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asha Support Only
Study NCT02651597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal
Study NCT02323178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: initial dose of 50 mg once daily, then the dose can be sequentially increased every 2 weeks up to a maximum dose of 300mg/day
Study NCT02230098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Study NCT01860378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full price
Description: Participants will receive a voucher for the full price of a Tdap vaccine ($63.99) + a baby care product voucher or gift card
Study NCT01860378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full price
Description: Participants will receive a voucher for the full price of a Tdap vaccine ($63.99) + a baby care product voucher or gift card
Study NCT01860378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: $5 off
Description: Participants will receive a voucher for $5 off a Tdap vaccine + a baby care product voucher or gift card.
Study NCT01860378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: $5 off
Description: Participants will receive a voucher for $5 off a Tdap vaccine + a baby care product voucher or gift card.
Study NCT02204501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 5mg Syrup
Description: All twenty four subjects will receive 5 mg midazolam syrup at four different time points during the study for a total of four non-subsequent dosing days.~* On Study Days 0 and 12, subjects will receive only 5 mg midazolam syrup dosed in the morning.~* On Study Days 6 and 9, subjects will have 5 mg midazolam syrup co-administered with their assigned dose of vapendavir in the morning. Co-administration of midazolam will not occur at the time of the evening dose for Group B.
Study NCT02204501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vapendavir 264 mg BID
Description: Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
Study NCT03559634 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. Contraceptive choices being offered include the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. The participant can then decide if they would like to start a medication they qualify for in the ED.
Study NCT03559634 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. This includes the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. Participants will then be given follow up information on outpatient locations where they can receive these contraceptive methods.
Study NCT02982707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Single oral dose
Study NCT04175717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy-led follow-up programme
Description: In this study arm, the participants will receive a nine weeks exercise programme and four education sessions. During the exercise programme, the patients will exercise twice per week under supervision and once by themselves. The supervised exercise sessions will consisted out of a combination of a cardiopulmonary and strength training and the unsupervised session will be an activity, which the participants like doing. Additionally, when the patient shows a reduced maximal inspiratory pressure (indication for a reduced diaphragm strength), the patient will also be ask to do an inspiratory muscle training at home. Furthermore, they will participate in education sessions, where they learn things about the intensive care unit, the post-intensive care syndrome, relaxation techniques and how to carry on with exercising.
Study NCT00699868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings
Description: Sampling of blood
Study NCT00699868 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings
Description: Sampling of blood
Study NCT01503554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Social Worker and Pharmacist Program
Description: Physician or nurse performs a med rec during hospital stay Clinical pharmacist completes an additional med rec of home meds, assesses med-related risks, and provides education After discharge, a Master's prepared social worker contacts the patient and conducts an assessment from a psychosocial perspective to identify any unmet needs.~Pharmacist will be available to patients should they have any medication-related questions post-discharge
Study NCT01503554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Intervention: Usual Care
Description: Patient receives usual care upon discharge from the hospital.
Study NCT00573664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: single oral dose of 600mg gabapentin
Study NCT00573664 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: Single dose
Study NCT05573152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: All previously selected patients will be under passive warming by means of blankets
Study NCT05573152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nursing
Description: All previously selected patients will be under active air flow warming device at 43 Celsius
Study NCT02071537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Dose is 50, 100, 150, and 200 mg per day cohorts. It is given one week prior to the initiation of chemotherapy and then given for four 21 day cycles in combination with chemotherapy.
Study NCT02071537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered day 1 of each 21 day cycle for 4-6 cycles.
Study NCT02071537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered days 1 and 8 of each 21 day cycle for 4-6 cycles.
Study NCT02190188 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wedge Insole 5mm
Study NCT02190188 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Knee Brace
Study NCT06001671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-109
Description: BEBT-109 is based on the 3+3 model, with a dose ascent starting from 120mg qd
Study NCT02281708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine plus cisplatin
Description: Drugs will be administered for 4 cycles, and should be administered at scheduled day +/- 3 days~* vinorelbine 25mg/m2 IV (Day 1, 8) q 3wks cisplatin 75mg/m2 IV (Day 1) q 3wks
Study NCT02518334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Description: 28 grams (2 drinks) of ethanol will be consumed either in the form of wine or vodka.
Study NCT02737358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine (NAC)
Description: NAC or matched placebo will be given to study participants for 8 weeks.
Study NCT02737358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo (2 capsules taken in the morning and evening) will be taken by study participants for eight weeks. All participants will receive brief smoking cessation counseling and support.
Study NCT03210740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM001 Cream, 7.5%
Description: Active Cream
Study NCT03210740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Placeo
Study NCT02600117 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg, oral, once a day
Study NCT04882371 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Neoadjuvant Chemotherapy for Breast Cancer
Study NCT04882371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Performed contrasted MRI for evaluate response of neoadjuvant chemotherapy
Study NCT04882371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Positron emission tomography - Copmputer Tomography (PET-CT)
Description: Performed contrasted PET-CT for evaluate response of neoadjuvant chemotherapy
Study NCT03587233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical assessment
Description: Besides the demographic features of the participants, the interventions on physical assessment will be performed including weight in kilogram and height in meter; and weight and height will be combined to report body mass index in kg/m2. The waist circumference will be measured to understand the central fattening from costal margins or above umbilicus in cm. If it is measured above 95cm for men and 80cm for women is considered as higher than normal; if higher than 110cm for men and 88cm for women is considered as having risks for obesity, diabetes, cardiovascular diseases etc. Hand and pinch grip power will be assessed. It the elbow is in extension upper extremity power, and if it is flexed at 90 degree and forearm is supported on the table handgrip power is to assess.
Study NCT03587233 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Analyses of body composition
Description: The analyzes of body composition will be measured with bioelectrical impedance analysis method by a body composition analyzer.